^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    AmoyDx Super-ARMS® EGFR Mutation Detection Kit

    Company:
    Amoy Diagnostics
    Type:
    CE Marked
    Related tests:
    Evidence Level:
    Sensitive: C3 – Early Trials

    [EGFR mutation-Non Small Cell Lung Cancer-erlotinib]

    Source:
    Signal Transduct Target Ther
    Test:

    AmoyDx Super-ARMS® EGFR Mutation Detection Kit

    Title:
    Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial
    Published date:
    02/24/2023
    Excerpt:
    ...the updated analysis of CTONG1103 indicated that erlotinib continued to improve PFS and OS numerically compared with platinum-based chemotherapy. Moreover, there was no evidence of cumulative toxicity in erlotinib during the long-term follow-up. The present results support the use of erlotinib in both the neoadjuvant and adjuvant settings for resectable stage IIIA-N2 EGFR-mutant NSCLC.
    DOI:
    https://doi.org/10.1038/s41392-022-01286-3
    Trial ID:
    EMERGING